BioMarin's VOXZOGO Shows Positive Phase 3 Results for Hypochondroplasia
Event summary
- BioMarin's Phase 3 CANOPY-HCH-3 study of VOXZOGO in hypochondroplasia showed statistically significant improvements in growth metrics, including annualized growth velocity (2.33 cm/year) and standing height (2.35 cm).
- The study results were published in NEJM Evidence and presented at the ESPE 2026 Annual Meeting.
- BioMarin submitted a supplemental New Drug Application (sNDA) to the FDA for VOXZOGO's use in hypochondroplasia, targeting a potential 2027 launch.
- VOXZOGO demonstrated a consistent safety profile with no treatment-related serious adverse events identified.
The big picture
BioMarin's positive Phase 3 results for VOXZOGO in hypochondroplasia position the company to potentially become the first to offer a targeted therapy for this rare genetic condition. The strategic move aligns with BioMarin's focus on rare disease treatments and could significantly expand its addressable market. The company's ability to secure regulatory approvals and demonstrate long-term efficacy will be critical to its success in this new indication.
What we're watching
- Regulatory Approval
- Whether the FDA will approve VOXZOGO for hypochondroplasia by 2027, making it the first targeted therapy for the condition.
- Market Expansion
- The pace at which BioMarin can expand VOXZOGO's market reach beyond achondroplasia to include hypochondroplasia.
- Long-term Efficacy
- How sustained the improvements in growth and quality of life metrics will be over longer-term follow-up.
Related topics